We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




Mailed Screening Kits Help Reduce Colorectal Cancer Screening Gaps

By LabMedica International staff writers
Posted on 28 May 2026

Colorectal cancer screening is a longstanding preventive priority, yet participation and follow-up remain uneven across patient groups. More...

Safety‑net primary care settings often face barriers that limit screening uptake among underserved populations. Addressing these gaps is essential to reduce disparities in outcomes. New findings demonstrate that mailing an at‑home stool test can substantially increase screening across diverse racial and ethnic groups.

At the University of North Carolina at Chapel Hill School of Medicine, investigators evaluated mailed fecal immunochemical tests (FIT) to increase colorectal cancer screening. The approach centered on sending FIT kits to patients due for screening at federally qualified health centers (FQHCs). For positive FIT results, the study team provided patient navigation to support follow‑up colonoscopy.

The analysis drew on data from two FQHC systems in North Carolina. A total of 3,734 patients were mailed FIT kits and participation in screening was assessed. Researchers reported an overall increase of 18.3 percentage points in colorectal cancer screening associated with the mailed‑test intervention.

Screening gains were similar among Hispanic, non‑Hispanic Black, and non‑Hispanic white patients. Among patients with a positive FIT who required follow‑up colonoscopy, the intervention’s effect was also similar across racial groups. However, Black patients were overall less likely to complete colonoscopy than white patients, indicating a need for additional, targeted strategies to support follow‑up among this population.

Results were published in the Annals of Family Medicine. The study team emphasized that mailed FIT programs can reach patients across demographic groups in community health settings while also highlighting persistent differences in colonoscopy completion that warrant focused interventions.

“This analysis showed that mailed colorectal cancer screening tests have the power to improve screening rates for diverse populations. This is really important, because we want these innovations in screening to improve outcomes among the hardest to reach populations and move the needle on colorectal cancer disparities,” said Anisha P. Ganguly, MD, MPH, a general internist at UNC Health and member of UNC Lineberger Comprehensive Cancer Center.

Related Links
UNC School of Medicine


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
H-FABP Assay
Heart-Type Fatty Acid-Binding Protein Assay
Hematology Consumables
Bioblood Devices
Creatinine/eGFR Meter
StatSensor® Creatinine/eGFR Meter
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Alzheimer’s pathology can start 15 to 20 years before symptoms, and validated tools that reach patients earlier help pave the way for earlier detection. (Image Credit: Adobe Stock)

Alzheimer’s Blood Test Becomes First FDA-Cleared Option for Adults as Young as 40

C2N Diagnostics’ PrecivityAD2 blood test was cleared by the U.S. Food and Drug Administration (FDA) on August 20, 2026, for adults as young as 40 who are experiencing signs of cognitive impairment, according... Read more

Pathology

view channel
Image: Adrenal gland tumor stained with hematoxylin and eosin (top) and CYP11B2 (bottom) (Photo courtesy of Christofer Juhlin)

Simple Immunohistochemical Size Ratio Improves Classification of Primary Aldosteronism

Primary aldosteronism is a common but underdiagnosed cause of hypertension, in which excess aldosterone promotes salt retention and raises blood pressure. Identifying the dominant source of hormone overproduction... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.